Overview
Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma
Status:
Completed
Completed
Trial end date:
2014-03-01
2014-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine the efficacy of indacaterol 55µg once daily (and 27.5 µg twice) in QVA149 compared to 75 µg indacaterol monotherapy.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis Pharmaceuticals
Criteria
Inclusion Criteria:- Asthma for at least 6 months, using inhaled corticosteroid for at least one month,
foreced breath test less than below the normal value of the general population, -show
an immediate improvement in breathing when given albuterol
Exclusion Criteria:
- patients who have smoked in the past 6 months or are currently smoking, including
those who smoked more than a pack of cigarettes a day for at least 10 years, -patients
who have a history of life-threatening asthma, -patients who have had an astham
attack, in the last 6 weeks, requiring use of systemic steroids, hospitalization, or
ER visit, -patients who have had a respiratory tract infection or worsening asthma
between screening or run-in periods, patients requring use of other asthma-related
drugs during the trial, other protocol-defined inclusion/exclusion may apply